Pedro Cahn REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires Etraviri
Pedro Cahn
REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007PEDRO CAHN, Juan A. Fernández Hospital, Buenos AiresEtravirine provides a chance to rescue patients who are failing non-nucleoside regimens according to 24-week pooled results of the DUET-1 and -2 studies. Nicola Solomon discussed these major trials withPedro Cahn, of Juan A. Fernández Hospital in Buenos Aires.
Tags
Related Episodes
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers
“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i
Audio Journal of Oncology Volume 16 Number 11
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology